230 related articles for article (PubMed ID: 35017485)
21. Rational design of a trimeric APRIL-based CAR-binding domain enables efficient targeting of multiple myeloma.
Schmidts A; Ormhøj M; Choi BD; Taylor AO; Bouffard AA; Scarfò I; Larson RC; Frigault MJ; Gallagher K; Castano AP; Riley LS; Cabral ML; Boroughs AC; Velasco Cárdenas RM; Schamel W; Zhou J; Mackay S; Tai YT; Anderson KC; Maus MV
Blood Adv; 2019 Nov; 3(21):3248-3260. PubMed ID: 31698455
[TBL] [Abstract][Full Text] [Related]
22. B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma.
Carpenter RO; Evbuomwan MO; Pittaluga S; Rose JJ; Raffeld M; Yang S; Gress RE; Hakim FT; Kochenderfer JN
Clin Cancer Res; 2013 Apr; 19(8):2048-60. PubMed ID: 23344265
[TBL] [Abstract][Full Text] [Related]
23. TACI, unlike BAFF-R, is solely activated by oligomeric BAFF and APRIL to support survival of activated B cells and plasmablasts.
Bossen C; Cachero TG; Tardivel A; Ingold K; Willen L; Dobles M; Scott ML; Maquelin A; Belnoue E; Siegrist CA; Chevrier S; Acha-Orbea H; Leung H; Mackay F; Tschopp J; Schneider P
Blood; 2008 Feb; 111(3):1004-12. PubMed ID: 17942754
[TBL] [Abstract][Full Text] [Related]
24. Development of systemic lupus erythematosus in NZM 2328 mice in the absence of any single BAFF receptor.
Jacob CO; Yu N; Guo S; Jacob N; Quinn WJ; Sindhava V; Cancro MP; Goilav B; Putterman C; Migone TS; Stohl W
Arthritis Rheum; 2013 Apr; 65(4):1043-54. PubMed ID: 23334904
[TBL] [Abstract][Full Text] [Related]
25. B cell activating factor (BAFF) and BAFF receptors: fakes and facts.
Ferraccioli G; Gremese E
Clin Exp Immunol; 2017 Dec; 190(3):291-292. PubMed ID: 28834574
[TBL] [Abstract][Full Text] [Related]
26. Antitumor efficacy of BAFF-R targeting CAR T cells manufactured under clinic-ready conditions.
Dong Z; Cheng WA; Smith DL; Huang B; Zhang T; Chang WC; Wang X; Forman SJ; Kwak LW; Qin H
Cancer Immunol Immunother; 2020 Oct; 69(10):2139-2145. PubMed ID: 32451682
[TBL] [Abstract][Full Text] [Related]
27. Synthetic CpG oligodeoxynucleotides augment BAFF- and APRIL-mediated immunoglobulin secretion.
Katsenelson N; Kanswal S; Puig M; Mostowski H; Verthelyi D; Akkoyunlu M
Eur J Immunol; 2007 Jul; 37(7):1785-95. PubMed ID: 17557373
[TBL] [Abstract][Full Text] [Related]
28. T Cells Genetically Modified to Express an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma.
Brudno JN; Maric I; Hartman SD; Rose JJ; Wang M; Lam N; Stetler-Stevenson M; Salem D; Yuan C; Pavletic S; Kanakry JA; Ali SA; Mikkilineni L; Feldman SA; Stroncek DF; Hansen BG; Lawrence J; Patel R; Hakim F; Gress RE; Kochenderfer JN
J Clin Oncol; 2018 Aug; 36(22):2267-2280. PubMed ID: 29812997
[TBL] [Abstract][Full Text] [Related]
29. Aberrant expression of BAFF by B lymphocytes infiltrating the salivary glands of patients with primary Sjögren's syndrome.
Daridon C; Devauchelle V; Hutin P; Le Berre R; Martins-Carvalho C; Bendaoud B; Dueymes M; Saraux A; Youinou P; Pers JO
Arthritis Rheum; 2007 Apr; 56(4):1134-44. PubMed ID: 17393395
[TBL] [Abstract][Full Text] [Related]
30. B cell-activating factor belonging to the TNF family acts through separate receptors to support B cell survival and T cell-independent antibody formation.
Shulga-Morskaya S; Dobles M; Walsh ME; Ng LG; MacKay F; Rao SP; Kalled SL; Scott ML
J Immunol; 2004 Aug; 173(4):2331-41. PubMed ID: 15294946
[TBL] [Abstract][Full Text] [Related]
31. Association of BAFF, APRIL serum levels, BAFF-R, TACI and BCMA expression on peripheral B-cell subsets with clinical manifestations in systemic lupus erythematosus.
Salazar-Camarena DC; Ortiz-Lazareno PC; Cruz A; Oregon-Romero E; Machado-Contreras JR; Muñoz-Valle JF; Orozco-López M; Marín-Rosales M; Palafox-Sánchez CA
Lupus; 2016 May; 25(6):582-92. PubMed ID: 26424128
[TBL] [Abstract][Full Text] [Related]
32. Investigating the Role of BAFF and Its Receptors in Renal Transplant Recipients with Chronic Antibody-Mediated Rejection.
Afzali S; Salehi S; Shahi A; Esmaeili M; Farashi Bonab S; Peykari A; Bagherpour F; Ansaripour B; Soleimanian T; Pour-Reza-Gholi F; Amirzargar A
J Immunol Res; 2021; 2021():6654992. PubMed ID: 33748289
[TBL] [Abstract][Full Text] [Related]
33. CAR T Cells with Enhanced Sensitivity to B Cell Maturation Antigen for the Targeting of B Cell Non-Hodgkin's Lymphoma and Multiple Myeloma.
Bluhm J; Kieback E; Marino SF; Oden F; Westermann J; Chmielewski M; Abken H; Uckert W; Höpken UE; Rehm A
Mol Ther; 2018 Aug; 26(8):1906-1920. PubMed ID: 30078440
[TBL] [Abstract][Full Text] [Related]
34. BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone.
Moreaux J; Legouffe E; Jourdan E; Quittet P; Rème T; Lugagne C; Moine P; Rossi JF; Klein B; Tarte K
Blood; 2004 Apr; 103(8):3148-57. PubMed ID: 15070697
[TBL] [Abstract][Full Text] [Related]
35. APRIL and BAFF proteins increase proliferation of human adipose-derived stem cells through activation of Erk1/2 MAP kinase.
Zonca M; Mancheño-Corvo P; DelaRosa O; Mañes S; Büscher D; Lombardo E; Planelles L
Tissue Eng Part A; 2012 Apr; 18(7-8):852-9. PubMed ID: 22059379
[TBL] [Abstract][Full Text] [Related]
36. Role of BAFF/BAFF-R axis in B-cell non-Hodgkin lymphoma.
Yang S; Li JY; Xu W
Crit Rev Oncol Hematol; 2014 Aug; 91(2):113-22. PubMed ID: 24629840
[TBL] [Abstract][Full Text] [Related]
37. Treatment of Multiple Myeloma Using Chimeric Antigen Receptor T Cells with Dual Specificity.
Globerson Levin A; Rawet Slobodkin M; Waks T; Horn G; Ninio-Many L; Deshet Unger N; Ohayon Y; Suliman S; Cohen Y; Tartakovsky B; Naparstek E; Avivi I; Eshhar Z
Cancer Immunol Res; 2020 Dec; 8(12):1485-1495. PubMed ID: 33008840
[TBL] [Abstract][Full Text] [Related]
38. Lymphoma B cells evade apoptosis through the TNF family members BAFF/BLyS and APRIL.
He B; Chadburn A; Jou E; Schattner EJ; Knowles DM; Cerutti A
J Immunol; 2004 Mar; 172(5):3268-79. PubMed ID: 14978135
[TBL] [Abstract][Full Text] [Related]
39. BAFF promotes T cell activation through the BAFF-BAFF-R-PI3K-Akt signaling pathway.
Hu S; Wang R; Zhang M; Liu K; Tao J; Tai Y; Zhou W; Wang Q; Wei W
Biomed Pharmacother; 2019 Jun; 114():108796. PubMed ID: 30921706
[TBL] [Abstract][Full Text] [Related]
40. TACI haploinsufficiency protects against BAFF-driven humoral autoimmunity in mice.
Jacobs HM; Arkatkar T; Du SW; Scharping NE; Woods J; Li QZ; Hudkins KL; Alpers CE; Rawlings DJ; Jackson SW
Eur J Immunol; 2021 Sep; 51(9):2225-2236. PubMed ID: 34146342
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
